Applied Data Research

(Nashua, NH) – Autoimmune diseases can be considered one of the silent tragedies of human suffering. Leading a group of ailments that includes migraine, dementia, and depression, autoimmune conditions cause daily anguish for a significant portion of the population and yet remain underserved by the medical establishment and the healthcare community. The refractory nature of this family of diseases is routed in the complexities and genetic underpinnings of the human immune response, resulting in a set of disease targets that are at once physiologically ubiquitous and highly individualized.

Until recently, autoimmune disease patients were given little hope for effective treatment. But the convergence of improved elucidation of autoimmune disease mechanisms and the ability to design and manufacture recombinant proteins capable of attenuating the immune system cascade has led to systemic treatments that have demonstrated the ability to provide some degree of relief from autoimmune symptoms in a significant number of patients.

These developments are examined in a new and comprehensive report – Autoimmune Disease Therapeutics: Targets, Technologies and
Therapies. The report analyzes current autoimmune therapeutics and assesses the next generation of candidates and their probable impact on treatment options and the competitive landscape.

More information is available at www.applieddata.org .

Source: Applied Data Research